homocysteine has been researched along with valsartan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Hijleh, M; Garadah, T; Golbahar, J; Gumaa, K; Kassab, S; Senok, S; Wazir, J | 1 |
| Elenkova, A; Kirilov, G; Lozanov, V; Mitev, V; Orbetzova, M; Shigarminova, R; Zacharieva, S | 1 |
| Cai, S; Li, W; Luo, J; Yuan, W; Zeng, K; Zhang, D | 1 |
3 other study(ies) available for homocysteine and valsartan
| Article | Year |
|---|---|
The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Homocysteine; Hyperhomocysteinemia; Hypertrophy, Left Ventricular; Male; Organ Size; Rats; Rats, Inbred F344; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2006 |
Homocysteine, renin and aldosterone in patients with Cushing's syndrome.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; Cushing Syndrome; Female; Fluorescence Polarization Immunoassay; Homocysteine; Humans; Male; Metabolic Syndrome; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2008 |
LCZ696 Possesses a Protective Effect Against Homocysteine (Hcy)-Induced Impairment of Blood-Brain Barrier (BBB) Integrity by Increasing Occludin, Mediated by the Inhibition of Egr-1.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Blood-Brain Barrier; Blotting, Western; Drug Combinations; Early Growth Response Protein 1; Homocysteine; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Neuroprotective Agents; Occludin; Oxidative Stress; Valsartan | 2021 |